Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -1030.42% is in line with its 5-year average of -1058.91%, around the middle of its 5-year range (-2028.42%–-42.27%).
22.18% above its 12-month average of -1324.05%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1619.88%.
NET PROFIT MARGIN
-1030.42%
NET PROFIT MARGIN AVG TTM
-1324.05%
NET PROFIT MARGIN AVG 3Y
-1255.86%
NET PROFIT MARGIN AVG 5Y
-1058.91%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+22.18%
CURRENT VS 3Y AVG
+17.95%
CURRENT VS 5Y AVG
+2.69%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 526 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Caribou Biosciences, Inc.
Market Cap
$118.52M
Net Profit Margin
-1030.42%
TTM Avg
-1324.05%
3Y Avg
-1255.86%
5Y Avg
-1058.91%
Market Cap
$119.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$117.03M
Net Profit Margin
-422412.50%
TTM Avg
-387587.50%
3Y Avg
-197966.84%
5Y Avg
-131977.89%
Market Cap
$116.30M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$120.80M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$115.66M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$114.76M
Net Profit Margin
-586.74%
TTM Avg
-215.13%
3Y Avg
-125.58%
5Y Avg
-83.72%
Market Cap
$114.71M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$122.26M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $118.52M | -1030.42% | -1324.05% | -1255.86% | -1058.91% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Genelux Corporation (GNLX)vs › | $117.03M | -422412.50% | -387587.50% | -197966.84% | -131977.89% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.30M | -175.78% | -311.79% | -369.50% | -4193.27% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.80M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | -586.74% | -215.13% | -125.58% | -83.72% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.71M | -270.22% | -342.92% | -204.73% | -136.49% |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.58M | 31.95% | 15.97% | 7.99% | 5.33% |
Operating Margin
-1220.5%
Net Profit Margin
-1030.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1619.88% |
| 2026-03-31 | -1046.52% |
| 2025-12-31 | -672.11% |
| 2025-09-30 | -1253.32% |
| 2025-06-30 | -2028.42% |
| 2025-03-31 | -1699.58% |
| 2024-12-31 | -1708.71% |
| 2024-09-30 | -1713.64% |
| 2024-06-30 | -1088.25% |
| 2024-03-31 | -1697.57% |
| 2023-12-31 | -969.79% |
| 2023-09-30 | -42.27% |
| 2023-06-30 | -786.13% |
| 2023-03-31 | -800.80% |
| 2022-12-31 | -731.01% |
| 2022-09-30 | -806.75% |
| 2022-06-30 | -636.86% |
| 2022-03-31 | -716.52% |
| 2021-12-31 | -722.12% |
| 2021-09-30 | -527.38% |
| 2021-06-30 | -969.58% |
| 2021-03-31 | -829.70% |
| 2020-12-31 | -1494.21% |
| 2020-09-30 | -662.19% |
| 2020-06-30 | -22.08% |
| 2020-03-31 | -576.13% |
